APDM gait and balance measures fail to predict symptom progression rate in Parkinson's disease

• DOI: 10.3389/fneur.2022.1041014
• Publication Date: 2022-11-09T04:44:00Z
• Authors: D. Campbell Dewey; Shilpa Chitnis; Morgan C. McCreary; Ashley Gerald; Chadrick H. Dewey; Alexander Pantelyat; Ted M. Dawson; Liana S. Rosenthal; Richard B. Dewey
• Keywords: clinical trials; 03 medical and health sciences; disease progression; 0302 clinical medicine; Neurology; Parkinson's disease; balance; Neurology. Diseases of the nervous system; gait; RC346-429

Parkinson's disease (PD) results in progressively worsening gait and balance dysfunction that can be measured using computerized devices. We utilized the longitudinal database of Disease Biomarker Program to determine if baseline measures predict future rates symptom progression. included 230, 222, 164, 177 PD subjects with 6, 12, 18, 24 months follow-up, respectively, we defined progression as following clinical parameters: MDS-UPDRS total score, Montreal Cognitive Assessment, PDQ-39 mobility subscale, levodopa equivalent daily dose, Schwab England global composite outcome. developed ridge regression models independently estimate how each or measure, combination measures, predicted The accuracy model was calculated by cross-validation which 90% data were used then tested on 10% left out. While modestly change outcomes at 6-month follow-up visit (accuracy range 66–71%) there no outcome variables during this short (median score = 0 LEDD 0). At periods months, failed held-out sets ranged from 42 60%). conclude set performed is unlikely help PD. Research scientists must continue search for predictors enhance performance modifying trials.